75 related articles for article (PubMed ID: 11102898)
1. Circulating antibodies to p40(AIS) in the sera of respiratory tract cancer patients.
Yamaguchi K; Patturajan M; Trink B; Usadel H; Koch W; Jen J; Sidransky D
Int J Cancer; 2000 Nov; 89(6):524-8. PubMed ID: 11102898
[TBL] [Abstract][Full Text] [Related]
2. AIS is an oncogene amplified in squamous cell carcinoma.
Hibi K; Trink B; Patturajan M; Westra WH; Caballero OL; Hill DE; Ratovitski EA; Jen J; Sidransky D
Proc Natl Acad Sci U S A; 2000 May; 97(10):5462-7. PubMed ID: 10805802
[TBL] [Abstract][Full Text] [Related]
3. Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer.
Tomkiel JE; Alansari H; Tang N; Virgin JB; Yang X; VandeVord P; Karvonen RL; Granda JL; Kraut MJ; Ensley JF; Fernández-Madrid F
Clin Cancer Res; 2002 Mar; 8(3):752-8. PubMed ID: 11895905
[TBL] [Abstract][Full Text] [Related]
4. Anti-p53 antibodies in serum of smokers and head and neck cancer patients.
Wollenberg B; Jan NV; Pitzke P; Reiter W; Stieber P
Anticancer Res; 1997; 17(1A):413-8. PubMed ID: 9066686
[TBL] [Abstract][Full Text] [Related]
5. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
Qiu LL; Hua PY; Ye LL; Wang YC; Qiu T; Bao HZ; Wang L
Cancer Detect Prev; 2007; 31(1):45-9. PubMed ID: 17292563
[TBL] [Abstract][Full Text] [Related]
6. Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma.
Iizasa T; Fujisawa T; Saitoh Y; Hiroshima K; Ohwada H
Cancer Immunol Immunother; 1998 Aug; 46(6):345-9. PubMed ID: 9756419
[TBL] [Abstract][Full Text] [Related]
7. A new prognostic indicator for head and neck cancer--p53 serum antibodies?
Gottschlich S; Folz BJ; Goeroegh T; Lippert BM; Maass JD; Werner JA
Anticancer Res; 1999; 19(4A):2703-5. PubMed ID: 10470224
[TBL] [Abstract][Full Text] [Related]
8. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP
Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237
[TBL] [Abstract][Full Text] [Related]
9. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma.
Bourhis J; Lubin R; Roche B; Koscielny S; Bosq J; Dubois I; Talbot M; Marandas P; Schwaab G; Wibault P; Luboinski B; Eschwege F; Soussi T
J Natl Cancer Inst; 1996 Sep; 88(17):1228-33. PubMed ID: 8780633
[TBL] [Abstract][Full Text] [Related]
10. Measurement and evaluation of serum anti-p53 antibody levels in patients with lung cancer at its initial presentation: a prospective study.
Segawa Y; Kageyama M; Suzuki S; Jinno K; Takigawa N; Fujimoto N; Hotta K; Eguchi K
Br J Cancer; 1998 Sep; 78(5):667-72. PubMed ID: 9744508
[TBL] [Abstract][Full Text] [Related]
11. MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis.
Rabassa ME; Croce MV; Pereyra A; Segal-Eiras A
BMC Cancer; 2006 Oct; 6():253. PubMed ID: 17064405
[TBL] [Abstract][Full Text] [Related]
12. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
13. Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck.
Lavieille JP; Lubin R; Soussi T; Reyt E; Brambilla C; Riva C
Anticancer Res; 1996; 16(4C):2385-8. PubMed ID: 8816839
[TBL] [Abstract][Full Text] [Related]
14. Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies.
Moch C; Moysan A; Lubin R; de la Salmonière P; Soufir N; Galisson F; Vilmer C; Venutolo E; Le Pelletier F; Janin A; Basset-Séguin N
Br J Cancer; 2001 Dec; 85(12):1883-6. PubMed ID: 11747330
[TBL] [Abstract][Full Text] [Related]
15. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies.
Looi K; Megliorino R; Shi FD; Peng XX; Chen Y; Zhang JY
Oncol Rep; 2006 Nov; 16(5):1105-10. PubMed ID: 17016600
[TBL] [Abstract][Full Text] [Related]
16. [Antibody formation to cellular p53 protein in patients with squamous cell carcinomas of the upper respiratory and digestive system].
Maass JD; Gottschlich S; Lippert BM; Niemann AM; Görögh T; Werner JA
Laryngorhinootologie; 1996 Jan; 75(1):53-6. PubMed ID: 8851121
[TBL] [Abstract][Full Text] [Related]
17. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations.
Ralhan R; Nath N; Agarwal S; Mathur M; Wasylyk B; Shukla NK
Clin Cancer Res; 1998 Sep; 4(9):2147-52. PubMed ID: 9748133
[TBL] [Abstract][Full Text] [Related]
18. Serum p53 antibodies as early markers of lung cancer.
Lubin R; Zalcman G; Bouchet L; Trédanel J; Legros Y; Cazals D; Hirsch A; Soussi T
Nat Med; 1995 Jul; 1(7):701-2. PubMed ID: 7585154
[TBL] [Abstract][Full Text] [Related]
19. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck.
Ito D; Visus C; Hoffmann TK; Balz V; Bier H; Appella E; Whiteside TL; Ferris RL; DeLeo AB
Int J Cancer; 2007 Jun; 120(12):2618-24. PubMed ID: 17294448
[TBL] [Abstract][Full Text] [Related]
20. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
